Deferoxamine Improves Left Ventricular Function in ß-Thalassemia
D Grisaru, AW Goldfarb, MS Gotsman… - Archives of internal …, 1986 - jamanetwork.com
• Serial echocardiographic examinations were made to study the changes in left ventricular
(LV) function and wall mass in 35 patients with thalassemia followed up for 5.5±2 years
(mean±SD). Twenty patients received deferoxamine sulfate for 2.0±0.6 years (drug group)
and 15 patients did not (nondrug group). Repeated blood transfusions were used to
maintain the pretransfusion hemoglobin levels at 9 g/dL (90 g/L). Deferoxamine therapy
improved LV function and decreased LV wall mass. Percentage shortening of LV diameter …
(LV) function and wall mass in 35 patients with thalassemia followed up for 5.5±2 years
(mean±SD). Twenty patients received deferoxamine sulfate for 2.0±0.6 years (drug group)
and 15 patients did not (nondrug group). Repeated blood transfusions were used to
maintain the pretransfusion hemoglobin levels at 9 g/dL (90 g/L). Deferoxamine therapy
improved LV function and decreased LV wall mass. Percentage shortening of LV diameter …
